💊
Cerezyme
imiglucerase
De ziekte van Gaucher
✅ Geautoriseerd
✅
Geen actieve meldingen
Dit geneesmiddel heeft geen lopende tekorten, veiligheidsbrieven of terugroepacties.
Waarvoor het wordt gebruikt
Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: anaemia after exclusion of other causes, such as iron deficiency Thrombocytopenia Bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly
⚠️ Patiëntveiligheid
No
📚 Voorgaande meldingen (2)
Officiële EMA-pagina
https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme